A Phase 4 interventional study of Compound Danshen Dropping Pills and Placebo in Microvascular Angina, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Qilu Hospital of Shandong University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Microvascular Angina with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Microvascular Angina · China.
Among the 15 studies in Microvascular Angina with a site in China, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 7 in phase 4, and was the 8th registered.
111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.
Browse Microvascular Angina studies →9 of the 15 studies in Microvascular Angina with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
Henan Institute of Cardiovascular Epidemiology · Sites in China
Ages 18–85
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Qilu Hospital of Shandong University · Sites in China
Ages 40–75
The Affiliated Hospital of Xuzhou Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 7
First in 2015; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 63 interventional studies indexed under Microvascular Angina.
Median enrollment 220 across the 10 interventional studies, 335 across the 5 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Qilu Hospital of Shandong University has 6 studies filed under Microvascular Angina — fewer than ten, so there is no comparison to draw.
2 of the studies in Microvascular Angina with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06727890Qilu Hospital of Shandong UniversityCompound Danshen Dripping Pill for Diabetic Microvascular Angina | 2026-12-31 |
| NCT06092736Qilu Hospital of Shandong UniversityMicrovascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Microvascular Angina with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary microvascular disease (MVD) refers to exertional angina or myocardial ischemia caused by abnormal structure and/or function of precoronary arterioles and arterioles under the action of various pathogenic factors. The symptoms of patients with coronary microvascular disease are mainly exertion-related chest pain episodes.
The basic and clinical researches of the traditional Chinese medicine compound Danshen dropping pills have found that it can improve vascular endothelial function and relieve angina pectoris, and it is widely used in clinical practice.
This is a randomized, double-blind, placebo-controlled, multicenter clinical study of Compound Danshen Dropping Pills and blank control in patients with microvascular angina pectoris.
The experimental drug and control drug of this clinical trial were selected according to the ratio of 1:1 patients were enrolled in the pre-experiment.
After the selected patients signed the informed consent, they were divided into a compound Danshen dripping pill treatment group and a placebo group according to a random, double-blind, placebo-controlled method. Dosage of Compound Danshen Dropping Pills or placebo: 20 capsules each time, 3 times a day, for a total of 6 months. Follow-up was performed every 2 months for a total of 6 months.
Primary study endpoints is the difference of the left anterior descending coronary flow reserve (CFR) measured by ultrasound between the two groups compared with the baseline.
Secondary study endpoint include the Number of angina attacks per week, the time of angina pectoris and the time of ischemic ST segment depression in exercise test.
Research Background Coronary microvascular disease (MVD) is a clinical syndrome refers to laboratory evidence of exertional angina or myocardial ischemia caused by structural and/or functional abnormalities of precoronary arterioles and arterioles under the influence of multiple pathogenic factors.. The main symptoms of patients with coronary microvascular disease are exertion-related chest pain attacks. It is difficult to distinguish patients with coronary microvascular disease from patients with severe coronary stenosis based on symptoms alone. However, the following clinical characteristics suggest that patients have coronary microvascular disease. It is more likely. First of all, it is more common in women, accounting for about 56%-79% of patients with coronary microvascular disease. However, most female patients with coronary microvascular disease have their first symptoms after menopause, which is no different from traditional female coronary heart disease patients. Secondly, most of the symptoms are induced by exertion, but it is not uncommon to have patients with silent chest pain. There are fewer patients with coronary microvascular disease who simply present with silent chest pain. Impaired coronary dilatation, increased sympathetic stimulation and sensitivity, and exercise-mediated coronary constriction can lead to the development of coronary microvascular dysfunction and reduced coronary flow reserve. Long-term recurrent angina pectoris attacks affect the patient's quality of life. Patients with significantly reduced coronary blood flow reserve or myocardial perfusion reserve, especially female patients, may have a higher incidence of adverse cardiovascular events.
Regarding drug treatment, traditional anti-ischemic treatment methods are currently recommended, including β- blockers, calcium ion antagonists and nitrates. If symptoms persist, other drugs include angiotensin-converting enzyme inhibitors, statins, ivabradine , ranolazine , and estrogen drugs. However, there is no specific clinical drug treatment. Basic and clinical studies of the traditional Chinese medicine Compound Danshen Dripping Pill have found that it can improve vascular endothelial function and relieve angina pectoris, and is widely used in clinical practice. However, its effect on coronary reserve function and angina pectoris in coronary microvascular disease needs further clinical research to confirm.
The active ingredients of compound Danshen dripping pills are water-soluble phenolic acids such as salvia miltiorrhiza and Panax notoginseng saponins. During the preparation process, borneol and auxiliary materials are added, and a highly dispersed solid dispersion is made through a specific process. The active ingredients of the drug have high purity, are evenly dispersed, and can be quickly absorbed through the mucous membrane. The dripping pills have good solid dispersion effect. The principle is to melt the drug ingredients and matrix into a solid solution, and the active ingredients of the drug are in the molecular state or in extremely fine form. The crystalline state is highly uniformly dispersed in the matrix, with fast drug dissolution and higher bioavailability. It can be taken sublingually and can quickly relieve angina pectoris and chest tightness.
Compound Danshen Dripping Pill has achieved a full-process quality control method from medicinal materials, intermediates to preparations (GAP-GEP-GMP) through the multi-factor fingerprint quality control system of compound oral Chinese medicine preparations, further improving the full-process quality control system of Compound Danshen Dripping Pill , after testing and analyzing nearly 200 batches of Compound Salvia Miltiorrhizae Dropping Pills Extract and Compound Salvia Miltiorrhizae Dropping Pills, the similarity is over 90%, and the quality of the products is stable between batches. It has been confirmed through the toxicology study of Compound Danshen Dripping Pill and the clinical use of hundreds of millions of people: it has no toxicity, few adverse reactions, and is safe and reliable for long-term use.
As a Chinese patent medicine for the treatment of stable angina pectoris, Compound Danshen Dripping Pill are included in Category A of the 2018 National Essential Drugs Catalog and the 2019 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue. Under the name of "Compound Danshen Dripping Pill", it has been written into more than 20 national medical guidelines or consensus, 15 of which involve the cardiovascular field, including "Guidelines for Rational Medication in Coronary Heart Disease (2nd Edition)", "Acute Myocardial Medication "Guidelines for the Diagnosis and Treatment of Infarction by Integrated Traditional Chinese and Western Medicine", "Chinese Expert Recommendations on the Clinical Application of Compound Danshen Dripping Pill", "Expert Consensus on the Diagnosis and Treatment of Atherosclerosis by Integrated Traditional Chinese and Western Medicine", etc.
In terms of international evidence-based research, large-sample, randomized, double-blind, placebo-controlled RCT studies were used, and 1,004 patients were included in phase III clinical studies at 127 centers in 9 countries/regions around the world, indicating that the US FDA-Phase III The main clinical efficacy indicators: significantly increase the patient's exercise flat time and improve exercise tolerance. Compared with the increase time of exercise oxygen tolerance of similar drugs, Compound Danshen Dripping Pill has obvious advantages . Secondary efficacy indicators: effectively reduce the number of angina attacks per week and significantly reduce the weekly nitroglycerin dosage.
In terms of domestic evidence-based research: 1011 studies on Compound Danshen Dripping Pill for the treatment of stable angina, 16 Meta-analyses, with a total enrollment of more than 100,000 people; 137 studies on the treatment of peri-PCI/ thrombolysis period , the total number of participants exceeds 10000 ; there are 36 studies on Compound Danshen Dripping Pill improving coronary microcirculation disorders, filling the gap in Western medicine treatment.
Systematic study of Compound Danshen Dripping Pill combined with Western medicine in the treatment of coronary heart disease angina pectoris: 21 articles were included, with a total number of cases of 2229. Compound Danshen Dripping Pill combined with Western medicine can benefit patients with coronary heart disease angina pectoris, especially in improving clinical symptoms and electrocardiogram . It has outstanding effects on ischemic state and regulating cholesterol levels.
A meta-analysis based on PubMed, EMBASE, CNKI, and Wanfang databases studied the efficacy of aspirin combined with Compound Danshen Dripping Pill in the treatment of coronary heart disease. The analysis included 14 randomized controlled trials with a total of 1,367 patients. The results showed that the combination Compared with aspirin alone, the drug can achieve more significant therapeutic effects in relieving angina pectoris symptoms and lowering blood lipids. Lu Yuhong et al. randomly divided 128 patients with coronary heart disease into groups. The control group took oral aspirin on the basis of conventional treatment, and the observation group took Danshen Dropping Pills on the basis of conventional treatment. After 2 months, the total clinical effective rate of the patients in the observation group was significantly higher than Control group. Compared with before treatment, the maximum platelet aggregation rate and thromboxane B2) levels of the two groups of patients were significantly reduced, and the decrease in the observation group was more obvious than that in the control group . The "Guidelines for the Diagnosis and Treatment of Integrated Traditional Chinese and Western Medicine in Acute Myocardial Infarction", led by Academicians Chen Keji, Academician Ge Junbo, and Professor Zhang Minzhou, were formulated in conjunction with experts in the fields of traditional Chinese medicine, Western medicine, integrated traditional Chinese and Western medicine, and methodology across the country. The guideline clearly states that Compound Danshen Dripping Pill are recommended for the treatment of acute myocardial infarction. The recommendation level is the highest in the guideline. Compound Danshen Dripping Pill can relieve chest pain, reduce the patient's risk of cardiac death, and improve the patient's cardiac function. and the role of quality of life.
4.2 Research design : Randomized, double-blind, placebo parallel-controlled, multi-center clinical study.
Note: The batch number on the drug packaging is unified as " 161299 ". 5. Research objects 5.1 Source of patients: patients with chest pain who had no obvious coronary artery stenosis on coronary angiography or coronary CT examination were admitted to the hospital outpatient clinics and wards .
5.2Selection criteria _
6.2 Random grouping The randomization method adopts the central randomization method. The central randomization system uses DAS2.1.1 software to generate random numbers (00 1 -100) and drug packaging numbers ( B ZH001-100 ). The random numbers and drug packaging numbers are separated in the system . The researcher passes the Apply to the system to obtain the drug packaging number for the subject. The random number and drug packaging number of the same subject are different, but their corresponding treatment plans are consistent within the system.
6.3 Research process After signing the informed consent form, the selected patients were divided into the Compound Danshen Dripping Pill treatment group and the placebo group according to a random, double-blind, placebo-controlled method. Dosage of Compound Danshen Dripping Pill or placebo: 3 times a day, 20 pills each time, for a total of 6 months . Follow-up visits were conducted every 2 months, and the follow-up period was 6 months in total .
6.4 Screening Phase
After signing the informed consent form, the following inspections will be performed: See Appendix 1 for inspection methods.
6.5 Enrollment and follow-up phase
7.2 Secondary observation indicators
8.Safety assessment Including clinical adverse reactions, laboratory indicators, etc. 9. Adverse event observation and reporting 9.1Definition of Adverse Events Adverse events refer to any adverse medical event that occurs to a patient in this clinical trial from the time the patient signs the informed consent form and is selected to participate in the trial to the last follow-up visit, regardless of whether this event is causally related to the above-mentioned drugs. .
NOTE: An adverse reaction may be any discomfort and unconscious signs (including abnormal laboratory test results), symptoms, or disease (new or worsening) related to the medication.
Events that meet the definition of adverse events include:
Events that do not meet the definition of an adverse event include:
There was no worsening of pre-existing diseases or conditions that were present or detected at the start of the trial, only expected day-to-day fluctuations.
Definition of serious adverse event " serious adverse event " is an adverse event that can occur at any dose and will:
Elective hospitalization that does not worsen a pre-existing condition compared with baseline is not an adverse event.
9.2 Adverse drug reactions Definition: Refers to harmful reactions that occur under normal usage and dosage of qualified drugs and have nothing to do with the purpose of medication.
Causal judgment indicators for adverse reaction judgment:
Item 1 : Is there a reasonable sequence between the time of starting medication and the time when the suspicion appears? Item 2 : Whether the suspected adverse reaction conforms to the known adverse reaction type of the drug; Item 3: Whether the suspected adverse reaction can be explained by the patient's pathological condition, concomitant medications, concomitant therapies, or previous therapies; Item 4 : After stopping the drug or reducing the dose, whether the suspected adverse reactions are reduced or disappeared; Item 5 : Whether the same reaction reappears after using the suspected drug again.
Causality judgment criteria: Judgment based on the order of the above five judgment indicators.
It is up to the investigator to evaluate possible associations between adverse events, trial drugs, and concomitant medications according to the table below.
Adverse reaction cause and effect judgment table
critical result Judgment index Project 1 Project 2 Project 3 Item 4 Item 5 Definitely related + + - + + probably related + + - + ? may be relevant + + ± ± ? suspicious + - ± ± ? Impossibly related + - + - -
Explanation: + Affirmation, - Negation, ± Difficult to affirm or deny,? The situation is unknown.
1.Based on the table above, determine the relationship between the following grade 5 adverse events and the drug.
( 1 ) Definitely related, ( 2 ) Probably related, ( 3 ) Possibly related, ( 4 ) Suspicious, ( 5 ) Impossibly related.
9.3Recording of adverse events on the basis of comprehensive consideration of comorbidities and concomitant medications, their relevance to the experiment should be evaluated. The relevance of the drug and documented in detail by the physician.
If an adverse event is discovered, the observing physician can decide whether to terminate the observation based on the condition. Cases of drug discontinuation due to adverse events should be followed up and investigated, and the results should be recorded in detail. If any abnormality in safety test indicators ( blood, urine, stool routine, electrocardiogram, liver function, kidney function ) occurs during or after treatment , the adverse event form should be filled in in a timely manner, reviewed at an appropriate time, and communicated with the subject A comprehensive analysis will be conducted on the onset, treatment, etc. to determine whether it is related to the experimental drug.
9.4 Handling of serious adverse events For any serious adverse events that occur during the trial ( including events requiring hospitalization, prolonged hospitalization, disability, affecting work ability, endangering life or death, causing congenital malformations, etc.) during the clinical trial , the researcher shall immediately respond to the patient's request. In addition to taking emergency measures, the subject must also immediately report to the ethics committee of the National Drug Clinical Trial Institution of Shandong University Qilu Hospital and the main research unit Tianjin Tasly Co., Ltd., the unit responsible for the research. The content of the report of serious adverse events should include: patient's name, random number, length of study participation, start date and stop date of serious adverse events, maximum intensity of serious adverse events, possible relationship between serious adverse events and study drugs, due to serious Whether the adverse event required a change in the study drug, the treatment given to the patient as a result of the serious adverse event, concomitant medications if the serious adverse event occurred, and the outcome of the serious adverse event.
10.2 Statistical analysis data set
10.3Statistical methods 9.3.1 Subject distribution analysis
Descriptive statistics Demographic information and other baseline characteristic values:
<!-- -->
10.3.4 Efficacy analysis (1) Analysis of main efficacy indicators FR measured by ultrasound at 6 months and the baseline between the two groups was compared using t test.
(2) Analysis of secondary efficacy indicators FR measured by ultrasound at 2 months and 4 months and the baseline was compared between the two groups using t test;
For the number of angina attacks per week, t test was used to compare the differences between groups;
For the time of occurrence of angina pectoris in exercise test, t test was used to compare the differences between groups;
The time when ischemic ST segment downward shift occurs in exercise test, and the t test is used to compare the differences between groups; 10.3.5 Security analysis (1) Calculate the incidence of adverse events/reactions, serious adverse events/reactions, and adverse events/reactions leading to dropout.
(2) List a detailed list of cases of various adverse events/reactions, serious adverse events/reactions, and adverse events/reactions leading to dropout.
(3) List the crosstabs of laboratory tests and electrocardiograms before and after medication.
(4) Descriptive statistics of changes from baseline in laboratory examinations, electrocardiograms, and vital signs, and actual measured values.
(5) Make a detailed list of abnormal values in laboratory tests, electrocardiograms, and physical examinations.
10.3.6Statistical software
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment group: Compound Danshen Dropping Pills (Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day, 20 capsules each time.
Drug: Compound Danshen Dropping Pills
Placebo group: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
Drug: Placebo
Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
The change of the left anterior descending coronary flow reserve (CFR)measured by echocardiography.
the difference of the left anterior descending coronary flow reserve (CFR) measured by ultrasound between the two groups.
Time frame: At the end of 6-month follow-up compared to the baseline
Number of angina attacks per week.
The differences in the number of angina attacks between the two groups.
Time frame: During 6 months of following up.
The time of angina pectoris in exercise test.
The differences in the time of angina pectoris in exercise test between the two groups.
Time frame: At the end of 6-month follow-up compared to the baseline.
The time of ischemic ST segment depression in exercise test.
The differences in the time of ischemic ST segment depression in exercise test between the two groups.
Time frame: At the end of 6-month follow-up compared to the baseline.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The investigators plan to share the study protocol,statistical Analysis Plan (SAP)and Informed Consent Form (ICF)of this research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The sharing time period is 6 months to 1 year after the data is released.
Access criteria: Share IPD under the conditions of protecting the privacy of patients and ensuring the safety of all diseases. It is necessary to contact the researcher and open the sharing authority after the researcher's consent.
Started Dec 2018 (actual). Primary completion is estimated for Jun 2027, 102 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →